Fellowship dates: 2011-2014
Research Emphasis:  Investigated the immune response to BCR-ABL induced leukemias and studied the response in the presence of nilotinib, a tyrosine kinase inhibitor, currently used to treat human ALL and CML patients to determine how TKI treatment affects the CD4 T-cell immune response to BCR-ABL induced leukemia.

Current Position: Field Director, Medical Science Liaisons, Inflammation and Autoimmunity, Incyte, Minneapolis, MN
Contact Info: [email protected]